<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133520</url>
  </required_header>
  <id_info>
    <org_study_id>November, 2016</org_study_id>
    <nct_id>NCT03133520</nct_id>
  </id_info>
  <brief_title>Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure</brief_title>
  <acronym>HFOT</acronym>
  <official_title>Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kursat Gundogan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effectiveness of high flow oxygen therapy in patients with hematologic malignancy acute
      hypoxemic respiratory failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory failure (ARF) is the leading reason for ICU admission in immunocompromised
      patients. Usual oxygen therapy involves administering low-to-medium oxygen flows through a
      nasal cannula or mask to achieve SpO2≥95%.

      High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to
      standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of
      higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired
      oxygen (FiO2) values of nearly 100%. Physiological benefits of HFNO consist of higher and
      constant FiO2 values, decreased work of breathing, nasopharyngeal washout leading to improved
      breathing-effort efficiency, and higher positive airway pressures associated with better lung
      recruitment.

      Clinical consequences of these physiological benefits include alleviation of dyspnea and
      discomfort, decreases in tachypnea and signs of respiratory distress, a diminished need for
      intubation in patients with severe hypoxemia, and decreased mortality in unselected patients
      with acute hypoxemic respiratory failure However, although preliminary data establish the
      feasibility and safety of this technique, HFNO has never been properly evaluated in
      immunocompromised patients.

      Thus, this project aims at demonstrating that HFNO is superior to low/medium-flow (standard)
      oxygen, minimizing day-28 mortality
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>First seven days</time_frame>
    <description>Intubation rate for each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>First 28 days</time_frame>
    <description>All-cause day-28 mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>patients comforts</measure>
    <time_frame>First 24 hours</time_frame>
    <description>Patient comfort with Visual Analogue Scale (VAS) score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Standard oxygen group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow oxygen therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow oxygen therapy</intervention_name>
    <description>High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.</description>
    <arm_group_label>High flow oxygen therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known immunosuppression defined as haematological malignancy.

          -  Need for oxygen therapy defined as with oxygen free arterial blood gas examination one
             or more of the following: (a) PaO2/FiO2&lt;300 mmHg (b) PaCO2≤45 mmHg (c) SaO2&lt;92%

          -  Respiratory distress with a respiratory rate &gt;22/min

        Exclusion Criteria:

          -  Refusal of study participation

          -  Pregnancy or breastfeeding

          -  Hypercapnia with a formal indication for non-invasive mechanical ventilation (NIMV)
             (PaCO2 ≥ 45 mmHg)

          -  Patients whose clinicians have decided on NIMV (Non-Invasive Mechanical Ventilation)
             and IMV (Invasive Mechanical Ventilation)

          -  Haemodynamic instability (mean arterial pressure &lt;65 mmHg)

          -  Vasopressor needs

          -  Awareness confusion and disorientation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kursat Gundogan, MD</last_name>
    <phone>+90 352 207 6666</phone>
    <phone_ext>21919</phone_ext>
    <email>kgundogan@erciyes.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nilgün Mendil, MD</last_name>
    <phone>+90 352 207 6666</phone>
    <phone_ext>20274</phone_ext>
    <email>namendil@yahoo.com.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erciyes University Medical School</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismail Kocyigit, MD</last_name>
      <phone>+903522076666</phone>
      <phone_ext>20000</phone_ext>
      <email>ikocyigit@erciyes.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Mustafa Kula, MD</last_name>
      <phone>+903522076666</phone>
      <phone_ext>20001</phone_ext>
      <email>mkula@erciyes.edu.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G. Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-30. doi: 10.1179/1607845412Y.0000000038. Epub 2012 Nov 15.</citation>
    <PMID>23321772</PMID>
  </reference>
  <reference>
    <citation>Lemiale V, Mokart D, Mayaux J, Lambert J, Rabbat A, Demoule A, Azoulay E. The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial. Crit Care. 2015 Nov 2;19:380. doi: 10.1186/s13054-015-1097-0.</citation>
    <PMID>26521922</PMID>
  </reference>
  <reference>
    <citation>Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.</citation>
    <PMID>25003980</PMID>
  </reference>
  <reference>
    <citation>Hernández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuena R, Fernández R. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Apr 5;315(13):1354-61. doi: 10.1001/jama.2016.2711.</citation>
    <PMID>26975498</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Kursat Gundogan</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Respiratory failure</keyword>
  <keyword>immuncompromise patients</keyword>
  <keyword>high flow oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

